Artículos del autor

solaci

Day 2

NEXT trial looked at a non-inferiority degradable polymer stent versus a second-generation permanent polymer stent.

Previous studies of non-inferiority (SORT-OUT III and V) compared the biodegradable polymer biolimus-eluting stent (BES) with permanent...
solaci -
Day 2

PRATO ACS: Rosuvastatin reduces the incidence of contrast nephropathy in patients with acute coronary syndrome who receive early invasive strategy

The aim of this study was to determine whether patients without ST-segment elevation acute coronary syndromes who...
solaci -
Day 1

TCT Session. An assessment of the severity of lesions. A debate about the different methods to assess coronary physiology.

FFR is the gold standard (Dr. William Fearon) Dr. William reported on the benefits of using FFR:  • A...
solaci -
Day 1

THRIVE: Niacin/laropiprant extended release showed no significant cardiovascular benefit.

The THRIVE study, (also known as HPS2-THRIVE), was a multicenter clinical trial designed to test the hypothesis...
solaci -
Day 1

TCT Session

Alan Wilson and Szeto Zajarias show that vascular complications of the trans-femoral path remain an important factor...
solaci -
Day 1

PREVAIL: LAA occlusion versus anticoagulation with warfarin to prevent stroke in patients with non-valvular atrial fibrillation.

An hour before the presentation of the PREVAIL study, the ACC announced the cancellation of the release...
solaci -
SOLACI Session

How to prevent TAVI complications with current technology

Antonio Dager2013-05-21
solaci -
SOLACI Session

TAVI: case complication

Marco Perin2013-05-21
solaci -